CA-VISA-INC
23.5.2023 09:01:35 CEST | Business Wire | Press release
Visa Inc. (NYSE: V), a global leader in digital payments, today announced that it plans to open a new global Technology and Product Hub in Poland that will be the first of its kind for Visa in Central and Eastern Europe. The Hub will house as many as 1,500 new tech and product hires over the next few years, as Visa invests worldwide to support its 24/7 development model for innovation and drives continued rapid growth in digital commerce and payments.
“Poland’s highly skilled workforce and vibrant IT sector make it an ideal location for us to recruit and collaborate with partners and businesses to develop new payment solutions,” said Rajat Taneja, President, Technology, Visa. “The next wave of our product and innovation roadmap is even more exciting as we focus on the next generation of AI, cybersecurity and the resilience and availability of our network for all who depend on it.”
Poland will serve as Visa’s fifth major strategic global Technology and Product Hub. As a growing location for top technology talent, it builds on Visa’s commitment to innovation and investment in the European region, and in Poland, in particular. Visa will find new ways to harness emerging talent in the region, accelerate product development and innovate at scale to bring value to consumers, clients, buyers and sellers around the world.
“As a global company that does business in more than 200 countries and territories, it is important to us to invest in local talent, creating regional tech hubs that allow us to serve our global customer base better than ever before,” said Charlotte Hogg, CEO, Visa, Europe. “We are committed to diversity and inclusion and ensuring that as Visa grows, it reflects the wide range of perspectives that make up the communities where we live and work. In Poland, this will mean bringing on board a diverse talent pool and welcoming talent from Ukraine and other parts of the region.”
“It is exceptionally good news that Visa, with its unique global experience and know-how, has chosen our country out of all possible locations, thus building Poland's position as the best place for investments in the new technology sector,” said Prime Minister of Poland, Mateusz Morawiecki. “Some of the factors that pointed to Poland as a location for this investment were the high qualifications of our IT staff and the significant pool of talent on the labor market. We have great potential to bring highly innovative investments to our country."
Visa has been at the forefront of digital payments for more than 60 years, operating in Poland since 1995. The first payment card in Poland was a Visa card and since the early digital days, Visa innovations have underpinned many of the ways that consumers and merchants pay and are paid. With Visa as a driving force in digital payments, Poland became the first market in the world to achieve 100% contactless availability.
Visa recognizes the critical role that digital skills play in the modern economy and is committed to supporting the EU’s efforts to build a more competitive and digitally savvy workforce.1 This investment underscores Visa’s pledge to promote digital inclusion and empower individuals to thrive in the digital age.
More details on Visa’s new global Technology and Product Hub will be shared in the coming months. Open roles in Poland can be found here.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating payments transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
1 Through the Digital Decade the EU aims to ensure that 20 million ICT specialists are in employment in the EU by 2030. https://ec.europa.eu/commission/presscorner/detail/en/ip_23_2246
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005524/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
